#stayhome Maintain the distance, wash your hands, and follow instructions from the health authorities.
RSS   Newsletter   Contact   Advertise with us

Onconova appoints Jack E. Stover to board

Share on Twitter Share on LinkedIn
Staff writer | Newtown, Pa., USA | May 24, 2016
OnconovaOnconova Therapeutics, a clinical-stage biopharmaceutical company, announced that Jack E. Stover has been appointed to its board of directors.
Currently, Mr. Stover serves as Interim President, CEO and Director of Interpace Diagnostics Group. Prior to his tenure at Interpace Diagnostics Group he served from August 2005 until December 2015 as Director, Member of the Special Executive Committee and Chairman of the Audit Committee of PDI.

Mr. Stover has served as President of Zebec Therapeutics, the successor to Quandrant Pharma, a position he has held since September 2012.

He formerly served as Executive Chairman of Targeted Nano Therapeutics from November 2008 to August 2012. He also served as Chief Executive Officer and Director of Antares Pharma from June 2004 to November 2008.

Mr. Stover joined Antares as President and COO rom SICOR. At SICOR, Inc., he served as Executive Vice President, Chief Financial and Operating Officer and Treasurer. For over 15 years prior, he was an employee of PricewaterhouseCoopers (previously Coopers & Lybrand), serving as a partner for over five years.

Mr. Stover is a certified public accountant and received his Bachelor’s Degree in Accounting and Finance from Lehigh University.


 LATEST MOVES FROM Pennsylvania 


MORE INSIDE POST